NCT07092358 Hereditary Ataxia Research on Multi-Omics and Neuroclinical Insights in the Yangtze Delta
| NCT ID | NCT07092358 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Hereditary Ataxia |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2035-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2025-06-01 with a primary completion date of 2035-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to explore the clinical and genetic characteristics, multi-omics profiles, disease mechanisms, biomarkers, and potential therapeutic targets of hereditary ataxia (HA) in patients diagnosed with HA, primarily in the Yangtze River Delta region of China. The main questions it aims to answer are: * What are the key pathogenic genetic variants, modifying factors and special inheritance patterns underlying HA? * How do multi-omics profiles correlate with clinical phenotypes, disease progress and mechanism in HA patients? * What are the implications of these findings for clinical practice? Participants will: * Undergo retrospective and prospective clinical data collection through long-term follow-up to observe disease onset, progression, and outcomes. * Provide biological samples (e.g., blood, skin) to establish a biobank for multi-omics analyses. * Be characterized using multidimensional omics technologies to identify disease-related molecular signatures, progression mechanisms, and potential regulatory targets.
Eligibility Criteria
Inclusion Criteria: * Presence of progressive ataxia as a primary or persistent clinical feature; * Sufficient evidence to exclude acquired causes of ataxia (e.g., chronic intoxication, immune-mediated inflammation, acquired vitamin deficiency, acute injury, stroke, infection, or space-occupying disorders); * For sporadic late-onset cases (≥30 years), disease duration must exceed 3 years, with no prominent progressive autonomic dysfunction or other features indicative of multiple system atrophy-cerebellar type (MSA-C); * Ability and willingness of the participant or legal guardian to provide informed consent and complete the entire study process. Exclusion Criteria: * Patients whose causative genes identified through genetic testing and analysis do not fall within the defined spectrum of hereditary ataxias, based on consensus classifications from the MDS Task Force on Genetic Movement Disorders and the SRCA Working Group, along with current research advancements; * Presence of concurrent cerebrovascular disease, brain tumors, or severe systemic illness; * Refusal to sign informed consent or provide biological samples by the participant or legal representative; * Inability or unwillingness to participate in follow-up assessments.
Contact & Investigator
Zhi-Ying Wu, M.D&Ph.D
STUDY CHAIR
Second Affiliated Hospital of Zhejiang University School of Medicine
Frequently Asked Questions
Who can join the NCT07092358 clinical trial?
This trial is open to participants of all sexes, studying Hereditary Ataxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07092358 currently recruiting?
Yes, NCT07092358 is actively recruiting participants. Contact the research team at jinyangyu@zju.edu.cn for enrollment information.
Where is the NCT07092358 trial being conducted?
This trial is being conducted at Hangzhou, China, Shanghai, China.
Who is sponsoring the NCT07092358 clinical trial?
NCT07092358 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The principal investigator is Zhi-Ying Wu, M.D&Ph.D at Second Affiliated Hospital of Zhejiang University School of Medicine. The trial plans to enroll 5,000 participants.